Liraglutide Counteracts Endoplasmic Reticulum Stress in Palmitate-Treated Hypothalamic Neurons without Restoring Mitochondrial Homeostasis

Int J Mol Sci. 2022 Dec 30;24(1):629. doi: 10.3390/ijms24010629.

Abstract

One feature of high-fat diet-induced neurodegeneration in the hypothalamus is an increased level of palmitate, which is associated with endoplasmic reticulum (ER) stress, loss of CoxIV, mitochondrial fragmentation, and decreased abundance of MC4R. To determine whether antidiabetic drugs protect against ER and/or mitochondrial dysfunction by lipid stress, hypothalamic neurons derived from pre-adult mice and neuronal Neuro2A cells were exposed to elevated palmitate. In the hypothalamic neurons, palmitate exposure increased expression of ER resident proteins, including that of SERCA2, indicating ER stress. Liraglutide reverted such altered ER proteostasis, while metformin only normalized SERCA2 expression. In Neuro2A cells liraglutide, but not metformin, also blunted dilation of the ER induced by palmitate treatment, and enhanced abundance and expression of MC4R at the cell surface. Thus, liraglutide counteracts, more effectively than metformin, altered ER proteostasis, morphology, and folding capacity in neurons exposed to fat. In palmitate-treated hypothalamic neurons, mitochondrial fragmentation took place together with loss of CoxIV and decreased mitochondrial membrane potential (MMP). Metformin, but not liraglutide, reverted mitochondrial fragmentation, and both liraglutide and metformin did not protect against either loss of CoxIV abundance or MMP. Thus, ER recovery from lipid stress can take place in hypothalamic neurons in the absence of recovered mitochondrial homeostasis.

Keywords: endoplasmic reticulum; liraglutide; metformin; mitochondria; obesity; palmitate.

MeSH terms

  • Animals
  • Endoplasmic Reticulum Stress
  • Hypothalamus / metabolism
  • Liraglutide* / pharmacology
  • Metformin* / metabolism
  • Metformin* / pharmacology
  • Mice
  • Mitochondria / metabolism
  • Neurons / metabolism
  • Palmitates / metabolism
  • Palmitates / pharmacology

Substances

  • Liraglutide
  • Palmitates
  • Metformin

Grants and funding

This research was funded by Sturgis Foundation Grant Award, UAMS College of Medicine, grant GR110030 to G.B.; by UAMS Provost’s Innovator Awards grant GR102402 to G.B.; and by 1R01AG071782 and to S.W.B. and the UAMS College of Medicine Creativity Hub Funding in Neurodegenerative Diseases.